id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-299560-np6nfvf2	Hendaus, Mohamed A.	Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary	2020-05-20		.txt	text/plain	2789	166	53	Replication of SARS-CoV-2 depends on the viral RNAdependent RNA polymerase (RdRp) (Elfiky & Azzam, 2020) which is the most probable target of the investigational nucleotide analogue remdesivir (RDV) (Agostini et al., 2018; Jordan et al., 2018; Siegel et al.,2017; Tchesnokov et al., 2019) . RDV exhibits broad-spectrum antiviral activity against RNA viruses, and former studies with RdRps from Ebola virus (EBOV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have shown that delayed chain-termination is RDV's conceivable mechanism of action ( Figure 2 ) (Agostini et al., 2018; Jordan et al., 2018; Siegel et al.,2017; Tchesnokov et al., 2019) . On April 29, 2020, Gilead revealed results from the openlabel, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in hospitalized patients with severe manifestations of COVID-19 disease.	./cache/cord-299560-np6nfvf2.txt	./txt/cord-299560-np6nfvf2.txt